YEHUD, Israel & NEW HOPE, Minn.--(BUSINESS WIRE)--BioControl Medical announced today that it has reached an important clinical trial milestone, reaching 480 randomized subjects – or 70 percent – of the planned 650 subjects with congestive heart failure (HF) in the INOVATE-HF (INcrease Of VAgal TonE in Heart Failure) trial of its CardioFit® system, the first medical device designed to treat HF using neurostimulation. With more than 65 participating centers in the United States and Europe, INOVATE-HF is the largest prospective, randomized global study ever to evaluate the treatment of HF with vagus nerve stimulation.
Help employers find you! Check out all the jobs and post your resume.
